GLP-1 receptor agonist
Semaglutide
Brand names: Ozempic, Wegovy, Rybelsus
Last reviewed 2026-08-01
Sex analysis reportedPregnancy/lactation data limited
Semaglutide is approved for type 2 diabetes and chronic weight management in several jurisdictions. Prespecified sex subgroup analyses are reported for some outcomes, but the trials were powered for overall efficacy. Pregnancy and lactation labeling should be reviewed directly.
Key takeaways
- Approved for type 2 diabetes and, at higher doses, chronic weight management.
- Sex-disaggregated efficacy and safety data are reported in some but not all trials.
- Reproductive labeling limits use in pregnancy; breastfeeding data are limited.
Medical disclaimer: Her Health Peptides publishes educational, source-linked summaries. We do not provide individualized medical advice, diagnosis, or treatment recommendations. Always talk with a licensed clinician about your specific situation, especially if you are pregnant, breastfeeding, planning pregnancy, or taking other medicines.